A story in the March 27, 2002, issue of BioWorld International about ReGen Therapeutics plc’s trials of colostrinin in the treatment of Alzheimer’s disease should have said the trials are at Phase IIa, and not Phase III as stated.

Editor’s Note: The correction has been made in BioWorld Online.